Multisystem inflammatory syndrome in children (MIS-C) cases by vaccination status in California

IF 4.5 3区医学 Q2 IMMUNOLOGY

Vaccine Pub Date : 2024-11-07 DOI:10.1016/j.vaccine.2024.126499

Chloe Le Marchand , Jason Robert C. Singson , Amy Clark , Dhawani Shah , Monice Wong , Sebastian Chavez , Marijoyce Naguit , Lauren Nelson , Hilary Rosen , Seema Jain , John J. Openshaw

{"title":"Multisystem inflammatory syndrome in children (MIS-C) cases by vaccination status in California","authors":"Chloe Le Marchand , Jason Robert C. Singson , Amy Clark , Dhawani Shah , Monice Wong , Sebastian Chavez , Marijoyce Naguit , Lauren Nelson , Hilary Rosen , Seema Jain , John J. Openshaw","doi":"10.1016/j.vaccine.2024.126499","DOIUrl":null,"url":null,"abstract":"<div><div>Multisystem inflammatory syndrome in children (MIS-C) is a rare condition occurring after SARS-CoV-2 infection in children under 21 years of age. Children (5–17 years) with MIS-C meeting the Centers for Disease Control (CDC) case definition were reported via California's passive disease surveillance system. Incidence of MIS-C was compared in unvaccinated and Pfizer-BioNTech vaccinated children aged 12–17 and 5–11 years. In the 12–17 year-old age group, there were 66 new cases among 872,936 unvaccinated children and 7 new cases among 2,117,575 vaccinated children. In the 5–11 year-old age group, there were 51 new cases among 2,113,725 unvaccinated children and 9 new cases among 1,221,293 vaccinated children. Compared with vaccinated children, the incident rate ratio of MIS-C was higher among unvaccinated children in both the 12–17-year-old group (22.9, 95 % confidence interval [CI]: 10.5–49.8, <em>p</em> < 0.0001) and the 5–11-year-old group (3.3, 95 % CI: 1.6–6.7, <em>p</em> = 0.0004). While MIS-C is rare, our results suggest that vaccination with the Pfizer-BioNTech vaccine is protective against MIS-C.</div></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"43 ","pages":"Article 126499"},"PeriodicalIF":4.5000,"publicationDate":"2024-11-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Vaccine","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0264410X24011812","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"IMMUNOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Multisystem inflammatory syndrome in children (MIS-C) is a rare condition occurring after SARS-CoV-2 infection in children under 21 years of age. Children (5–17 years) with MIS-C meeting the Centers for Disease Control (CDC) case definition were reported via California's passive disease surveillance system. Incidence of MIS-C was compared in unvaccinated and Pfizer-BioNTech vaccinated children aged 12–17 and 5–11 years. In the 12–17 year-old age group, there were 66 new cases among 872,936 unvaccinated children and 7 new cases among 2,117,575 vaccinated children. In the 5–11 year-old age group, there were 51 new cases among 2,113,725 unvaccinated children and 9 new cases among 1,221,293 vaccinated children. Compared with vaccinated children, the incident rate ratio of MIS-C was higher among unvaccinated children in both the 12–17-year-old group (22.9, 95 % confidence interval [CI]: 10.5–49.8, p < 0.0001) and the 5–11-year-old group (3.3, 95 % CI: 1.6–6.7, p = 0.0004). While MIS-C is rare, our results suggest that vaccination with the Pfizer-BioNTech vaccine is protective against MIS-C.

查看原文本刊更多论文

加利福尼亚州按疫苗接种状况分列的儿童多系统炎症综合征 (MIS-C) 病例。

儿童多系统炎症综合征（MIS-C）是 21 岁以下儿童感染 SARS-CoV-2 后出现的一种罕见病症。加利福尼亚州的被动疾病监测系统报告了符合美国疾病控制中心 (CDC) 病例定义的儿童（5-17 岁）多系统炎症综合征病例。对未接种疫苗的儿童和接种辉瑞生物技术公司疫苗的 12-17 岁和 5-11 岁儿童的 MIS-C 发病率进行了比较。在 12-17 岁年龄组中，872936 名未接种疫苗的儿童中有 66 例新病例，2117575 名接种疫苗的儿童中有 7 例新病例。在 5-11 岁年龄组中，未接种疫苗的 2,113,725 名儿童中有 51 例新病例，接种疫苗的 1,221,293 名儿童中有 9 例新病例。与接种过疫苗的儿童相比，在 12-17 岁年龄组中，未接种过疫苗的儿童的 MIS-C 发生率比率更高（22.9，95% 置信区间 [CI]：10.5-49.8，95% 置信区间 [CI]：10.5-49.8）：10.5-49.8, p

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Vaccine 医学-免疫学

CiteScore

8.70

自引率

5.50%

发文量

992

审稿时长

131 days

期刊介绍： Vaccine is unique in publishing the highest quality science across all disciplines relevant to the field of vaccinology - all original article submissions across basic and clinical research, vaccine manufacturing, history, public policy, behavioral science and ethics, social sciences, safety, and many other related areas are welcomed. The submission categories as given in the Guide for Authors indicate where we receive the most papers. Papers outside these major areas are also welcome and authors are encouraged to contact us with specific questions.